항당뇨약 Rosiglitazone의 혈관 수축성에 대한 이중성 조절

• 영문명: Biphasic Effects of Rosiglitazone on Agonist-induced Regulation of Vascular Contractility
• 발행기관: 대한약학회
• 저자명: 박진건(Jin Gun Park) 제현동(Hyun Dong Je)
• 간행물 정보: 『약학회지』제51권 제5호 (2007년), 301~306쪽, 전체 6쪽
• 주제분류: 의약학 > 기타의약학
• 파일형태: PDF
• 발행일자: 2007.10.31

영문 초록

Rosiglitazone (Avandia？？) represents a new class of antidiabetic drugs which are PPARŗ agonists. The present study was undertaken to determine whether the new antidiabetic rosiglitazone influences on the agonist-induced regulation of vascular smooth muscle contraction as an antihypertensive and, if so, to investigate the related mechanism. Endothelium-denuded arterial rings from male Sprague-Dawley rats were used and isometric contractions were recorded using a computerized data acquisition system. Rosiglitazone decreased Rho-kinase activating agonist (NaF or thromboxane A2mimetic)-induced contraction but not depolarization- or phorbol ester-induced contraction. Surprisingly, it slightly potentiated the latter contraction possibly opening a voltage-dependent calcium channel by its chemical structure on 50 mM KCI- or 1μM phorbol 12,13-dibutyrate-induced vasoconstriction. In conclusion, this study provides the evidence and possible related mechanism concerning the biphasic effect of an antidiabetic rosiglitazone as a possible antihypertensive on the agonistinduced contraction in rat aortic rings regardless of endothelial function.

키워드

KC1 NaF phorbol 12,13-dibutyrate Rho-kinase rosiglitazone thromboxane A2 mimetic